Courage Against Cancer
FOLFIRINOX-related fatigue typically peaks in the first few days after each infusion cycle and partially eases before the next cycle begins. However, cumulative fatigue often builds over multiple cycles and can persist for weeks to several months after treatment ends.
Treatment fatigue from FOLFIRINOX and gemcitabine is one of the most common and disruptive experiences reported by pancreatic cancer patients — and Courage Against Cancer (CAC) exists, in part, to help you navigate it. This isn’t ordinary tiredness.